Preferences help
enabled [disable] Abstract
Number of results
2013 | 8 | 5 | 553-557
Article title

The effect of orlistat on body weight in obese Czech adults

Title variants
Languages of publication
Physical description
1 - 10 - 2013
18 - 9 - 2013
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • Language Training Centre, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • [1] Reaven P., Metabolic syndrome, J. Insur. Med., 2004, 36, 132–142
  • [2] Ginter E, Simko V., Adult obesity at the beginning od the 21st century: epidemiology, pathophysiology and health risk, Bratisl. Lek. Listy, 2008, 109, 224–230
  • [3] Waden T.A, Berkowitz R.I, Womble L.G., Randomized trial of lifestyle modification and pharmacotherapy for obesity, N. Engl. J. Med., 2005, 353, 2111–2116[Crossref]
  • [4] Svendsen M, Tonstad S., Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders, Nutr. J., 2011, 8, 10–21 [WoS]
  • [5] Torp-Pedersen C, Caterson I, Coutinho W., Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial, Eur. Heart. J., 2007, 28(23), 2915–2923[WoS][Crossref]
  • [6] James W.P, Caterson I.D, Coutinho W., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects, N. Engl. J. Med., 2010, 363(10), 905–917[WoS][Crossref]
  • [7] Hainer V., Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care, 2011, 34, 349–354[Crossref][WoS]
  • [8] Bray G.A., Medical therapy for obesity, Mt. Sinai J. Med., 2010, 77(5), 407–417[Crossref]
  • [9] Li Z, Maglione M, Tu W., Pharmacologic treatment of obesity, Ann. Intern. Med., 2005, 142, 532–538[Crossref]
  • [10] Hainer V., Orlistat a perspektivy farmakoterapie obezity, JAMA, 1999, 7, 371–373
  • [11] Li M.F, Cheung B.M., Rise and fall of anti-obesity drugs, World J. Diabetes, 2011, 15(2), 19–23[Crossref]
  • [12] Jain S.S, Ramajane S.J, Akat P.B., Evaluation of efficacy and safety of orlistat in obese patients, Indian J. Endocrinol. Metab., 2011, 15(2), 99–104[Crossref]
  • [13] Derosa G, Maffioli P, Salvadeo S.A., Comparison of orlistat treatment and placebo in obese type 2 diabetic patients, Expert Opin. Pharmacother., 2010, 11(12), 1971–1982[Crossref][WoS]
  • [14] Minarčíková I., Farmakoekonomické aspekty ve farmakoterapii obezity, Česká a Slov. Farm., 2003, 52, 258–261
  • [15] Hainer V., Comment to the article: Assessment of morbid obesity treatment cost efficiency in the Czech Republic, Diab. Metab. Endokr., 2012, 15(3), 199–200
  • [16] Russell-Jones D., Gough S. Recent advances in incretin-based therapies, Clin. Endocrinol. 2012, 77(4), 489–499[WoS][Crossref]
  • [17] Hayes M.R., De Jonghe B.C., Kanoski S.E., Role of the glucagon-like-peptide-1 receptor in the control of energy balance, Physiology and Behavior, 2010, 100(5), 503–510[Crossref]
  • [18] Allison D.B., Gadde K.M., Garvey W.T., Controlledrelease phentermine/topiramate in severely obese adults: a randomized controlled trial, Obesity, 2012, 20(2), 330–42[WoS][Crossref]
  • [19] Gadde K.M., Day W.W., Low-dose, controlledrelease phentermin/topiramate for reduction of weight, Obesity reviews from 11th International Congress on Obesity, 11–15 July 2010 Stockholm, 2010, 11(1), 42–43
  • [20] Ornellas T., Chavez B., A New Approach to Weight Loss in Obese Adults, Pharmacy and Therapeutics, 2011, 36(5), 255–256, 261–262
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.